Scripta Insights Joins Eli Lilly TuneLab to Advance Neurodegenerative Drug Discovery

According to a recent LinkedIn post from Scripta Insights, the company is participating in Eli Lilly’s TuneLab program, which focuses on applying advanced computation to drug discovery. The post highlights that Scripta expects to leverage Lilly’s investment in predictive ADME and chemical profiling AI and ML tools, integrated via the Rhino Federated Computing platform.

The post suggests this collaboration may accelerate Scripta’s decision-making around its novel chemistry and potentially improve the efficiency of its discovery pipeline for neurodegenerative disease candidates. For investors, participation in TuneLab could signal enhanced R&D capabilities and external validation of Scripta’s biology-first approach, though any impact on timelines, partnerships, or valuation will depend on downstream data quality and eventual clinical progress.